SRR35579827
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.430
- ALLOGRAFT_REJECTION+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.330
- COAGULATION+0.280
- XENOBIOTIC_METABOLISM+0.260
- IL2_STAT5_SIGNALING+0.240
- FATTY_ACID_METABOLISM+0.210
- PANCREAS_BETA_CELLS+0.210
- APOPTOSIS+0.190
- ADIPOGENESIS+0.170
Top 10 suppressed
- E2F_TARGETS-0.630
- G2M_CHECKPOINT-0.560
- MYC_TARGETS_V2-0.430
- MITOTIC_SPINDLE-0.340
- WNT_BETA_CATENIN_SIGNALING-0.320
- ANGIOGENESIS-0.250
- HEDGEHOG_SIGNALING-0.220
- MTORC1_SIGNALING-0.220
- MYC_TARGETS_V1-0.210
- CHOLESTEROL_HOMEOSTASIS-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598330 | fetal | fetal | 0.810 |
| 2 | TCGA-44-2655-01A-01R-0946-07 | — | cohortA2 | 0.802 |
| 3 | SRR11296843 | — | — | 0.800 |
| 4 | TCGA-CQ-6222-01A-11R-1915-07 | — | — | 0.796 |
| 5 | ERR2598267 | fetal | fetal | 0.791 |
| 6 | TCGA-OR-A5LA-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.790 |
| 7 | MDT-AP-1333 | Med | Medulloblastoma | 0.789 |
| 8 | ERR2598283 | fetal | fetal | 0.785 |
| 9 | BS_EHVYJAVA | pilocytic astrocytoma | — | 0.779 |
| 10 | TCGA-49-4501-01A-01R-1206-07 | — | cohortA1 | 0.778 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.430 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.260 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.170 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.160 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.090 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.080 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.080 | Inavolisib | — uncovered |